BRCAura RUO
Research-use-only AI test assessing BRCA-related genomic risk signatures from pathology data, sold to research institutions rather than clinical end users.
Find alternatives to BRCAura RUO
What it does
- Medical imaging analysis
Sources
- Pricing
-
Official documentation · 14 Sep 2026
Sold to research institutions under an RUO (research-use-only) label; no public price. Whether a recurring free tier exists is not stated either way.
- Description
- What it does
-
Official documentation · 29 Oct 2026
Reads pathology slide images: "A histology model to predict germline BRCA1/2 mutations from HR+/HER2- breast cancer images", reading "digitized H&E slides". Same tag as TLS Detect.
- Sold within
-
Own page; RUO status confirmed in the product's own name and page copy -- sold to research institutions, not for clinical diagnostic use.
- Name
- URL
- Deployment
-
Official documentation · 29 Oct 2026
The test page does not state its delivery; Waiv's Destra page (https://waiv.com/precision-testing/destra) describes the platform that delivers all of Waiv's tests and lists "Scalable SaaS infrastructure" (Destra page, which describes itself as "a common platform enabling the easy access and use of all Waiv's digital pathology precision tests"). Nothing on any of these pages describes running on the user's own device.
- Modalities
-
Official documentation · 14 Oct 2026
Page: 'BRCAura RUO, an AI pathology product to support gBRCA mutation testing through analysis of morphological characteristics found in digitized H&E slides'.
- Intended for
Also from Waiv
-
Destra Platform
Workflow platform that orchestrates Waiv's diagnostic tests within a lab's existing pathology workflow, handling sample intake, result delivery and reporting.
-
MSIntuit Suite Data service
Suite of AI tests that screen digitised H&E slides for microsatellite instability, marketed as one branded product line: the colorectal test (MSIntuit CRC) is CE-IVD marked, and the endometrial and gastric tests (MSIntuit EC and GC) are in development and research-use-only.
-
RlapsRisk BC Data service
CE-IVDR-cleared AI diagnostic test that predicts breast-cancer recurrence risk from routine pathology data, spun out of Owkin's diagnostics division.
-
TLS Detect Data service
Research-use AI test that screens digitised H&E slides for tertiary lymphoid structures, a biomarker associated with response to immune checkpoint inhibitors, across tumour types and without a separate stain.
Something wrong here? Send a correction — quote this product id: waiv-brcaura-ruo.